Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Aug;154(2):293-302.
doi: 10.4103/ijmr.IJMR_4454_20.

Updates on systemic therapy for cervical cancer

Paul Gopu  1 , Febin Antony  1 , Sunu Cyriac  2 , Katherine Karakasis  3 , Amit M Oza  3
Affiliations
Review

Updates on systemic therapy for cervical cancer

Paul Gopu et al. Indian J Med Res. 2021 Aug.

Abstract

Cervical cancer is one of the most common cancers in the world both in terms of incidence and mortality, more so important in low- and middle-income countries. Surgery and radiotherapy remain the backbone of treatment for non-metastatic cervical cancer, with significant improvement in survival provided by addition of chemotherapy to radiotherapy. Survival as well as quality of life is improved by chemotherapy in metastatic disease. Platinum-based chemotherapy with/without bevacizumab is the mainstay of treatment for metastatic disease and has shown improvement in survival. The right combinations and sequence of treatment modalities and medicines are still evolving. Data regarding the molecular and genomic biology of cervical cancer have revealed multiple potential targets for treatment, and several new agents are presently under evaluation including targeted therapies, immunotherapies and vaccines. This review discusses briefly the current standards, newer updates as well as future prospective approaches in systemic therapies for cervical cancer.

Keywords: Cervical cancer; immunotherapy; systemic therapy; targeted therapy; update.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: None.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, et al. Estimates of incidence and mortality of cervical cancer in 2018:A worldwide analysis. Lancet Glob Health. 2020;8:e191–203. - PMC - PubMed
    1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108. - PubMed
    1. World Health Organization. Cancer today. [accessed on April 20, 2020]. Available from:http://gco.iarc.fr/today/home .
    1. Yang DX, Soulos PR, Davis B, Gross CP, Yu JB. Impact of widespread cervical cancer screening:Number of cancers prevented and changes in race-specific incidence. Am J Clin Oncol. 2018;41:289–94. - PMC - PubMed
    1. Brisson M, Kim JJ, Canfell K, Drolet M, Gingras G, Burger EA, et al. Impact of HPV vaccination and cervical screening on cervical cancer elimination:A comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet. 2020;395:575–90. - PMC - PubMed